ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

A propensity score–matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML.

Early evaluation of ABCB1 mRNA expression may help identify CML patients who are likely to be resistant to first- and second-generation tyrosine kinase inhibitors.

Maintenance therapy with TKIs following allogeneic HSCT is feasible and may improve outcomes in patients with high-risk Philadelphia chromosome–positive leukemia.

A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.

Patients with chronic myeloid leukemia who are treated with tyrosine kinase inhibitors could be at increased risk of long-term cardiovascular toxicity.

Two studies show that early deep responses with TKIs yield lasting positive outcomes in CML patients, and that dasatinib outperforms imatinib.

A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.

Pages

Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.